Erratum
for
Kaufman et al., J Clin Oncol 18 (9) 1921-1927.
Erratum
for
Bubley et al., J Clin Oncol 17 (11) 3461-3467.
Journal of Clinical Oncology, Vol 18, Issue 13
(July), 2000: 2644
© 2000 American Society for Clinical Oncology
Figure 2 in the article by Bubley et al, entitled "Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations from the Prostate-Specific Antigen Working Group" (J Clin Oncol 17:3461-3467, 1999), was incorrect.
View larger version (13K):
[in this window]
[in a new window]
|
Fig 2. The durations of both PSA-based reporting end points are measured from the first time point at which PSA has declined by at least 50% (which must eventually be confirmed by a second value). The duration of PSA response is the time until PSA has increased to 50% above the nadir. In addition, in many cases it will be possible (in retrospect) to identify an inflection point at which PSA began what became a continuous increase. Some investigators feel that this may be considered the point at which disease control could be assumed to be lost. Thus the duration of PSA control may also be reported.
|
|
The correct figure and legend are reprinted here.
The May 2000 article by Kaufman et al, "Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer" (J Clin Oncol 18:1921-1927, 2000), contained errors in Tables 1 and 2.
In Table 1, the correct number of patients with TCC was 44 (95.7%), and the correct number of patients with mixed TCC was two (4.3%). Table 2 omitted the last two columns. The corrected table is reprinted below.
|
